Results for vectibixi translation from Estonian to English

milleks vectibixi kasutatakse?
what is vectibix used for?

muu teave vectibixi kohta
other information about vectibix:

vectibixi toimeaine panitumumaab on monoklonaalne antikeha.
the active substance in vectibix, panitumumab, is a monoclonal antibody.

millist teavet vectibixi kohta veel oodatakse?
what information is still awaited for vectibix?

milles seisneb uuringute põhjal vectibixi kasulikkus?
what benefit has vectibix shown during the studies?

vectibixi kasutatakse metastaatilise käär- või pärasoolevähi raviks.
vectibix is used to treat metastatic cancer of the colon or rectum.

euroopa avaliku hindamisaruande täisteksti vectibixi kohta leiate siit.
the full epar for vectibix can be found here.

vectibixi kasutatakse käär - või pärasoole metastaatilise kartsinoomi raviks.
vectibix is used to treat metastatic carcinoma of the colon or rectum.

vectibixi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
for the full list of all side effects reported with vectibix, see the package leaflet.

töötati välja riskijuhtimiskava, et tagada vectibixi võimalikult ohutu kasutamine.
a risk management plan has been developed to ensure that vectibix is used as safely as possible.

mis meetmed võetakse, et tagada vectibixi ohutu ja efektiivne kasutamine?
what measures are being taken to ensure the safe and effective use of vectibix?

vectibixi toimet lisamisel parimale toetavale ravile võrreldi ainult parima toetava ravi toimega.
the effects of vectibix in addition to ‘best supportive care’ were compared with those of best supportive care alone.

vectibixi toimet selle lisamisel parimale toetavale ravile võrreldi ainult parima toetava ravi toimega.
the effects of vectibix in addition to ‘ best supportive care’ were compared with those of best supportive care alone.

euroopa komisjon andis vectibixi müügiloa, mis kehtib kogu euroopa liidu territooriumil, 3. detsembril 2007.
the european commission granted a conditional marketing authorisation valid throughout the european union for vectibix on 3 december 2007.

inimravimite komitee järeldas, et vectibixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
the chmp concluded that vectibix’s benefits are greater than its risks and recommended that it be given marketing authorisation.

selle alusel lisati vectibixi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for vectibix, including the appropriate precautions to be followed by healthcare professionals and patients.

uuringutes tekkis ligikaudu 93%-l vectibixi saanud patsientidest nahaga seotud kõrvalnähte, kuigi need olid enamasti kerged või mõõdukad.
in studies, 93% of the patients receiving vectibix had side effects affecting the skin, although most of these were mild or moderate.

lisaks esitab tootja selliste uuringute tulemused, milles selgitatakse senisest täpsemini, mis patsiendid reageerivad vectibixi-ravile paremini.
in addition, the company will provide the results of studies to try to further characterise those patients who respond better to vectibix.

vectibixi kasutamisel lisaks parimale toetavale ravile oli see aeg keskmiselt 12, 3 nädalat, võrreldes 7, 3 nädalaga ainult parimat toetavat ravi saanud patsientidel.
in the patients with non-mutated kras in their tumours, vectibix prolonged the time until the disease got worse or the patient died: this took an average of 12.3 weeks in the patients who took vectibix in addition to best supportive care, compared with 7.3 weeks in those who received best supportive care alone.

see sarnaneb ravivastuse määraga 78%, mida täheldati muteerumata ras-geeniga patsientidel, kes said vectibixi koos folfox-keemiaraviga.
this is similar to a response rate of 78% observed in patients with wild-type ras given vectibix with folfox.